Servier snags FDA approval for Voranigo, the first targeted therapy for a common type of brain tumor
Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. The approval represents the first major treatment advance in low-grade brain cancer in more than two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback